DYRK1A has become a target for DS drug development (Duchon and Herault 2016) and several molecules have been identified or developed to inhibit DYRK1A activity, including harmine, EGCG, INDY, FINDY, leucettine L41and CX‐4945 (Adayev et al. This evidence concerns the gene DYRK1A and Dravet syndrome.